BERKELEY, CA (UroToday.com) - Many men diagnosed with clinically localized prostate cancer electing to undergo radiotherapy will experience biochemical recurrence - with approximately 63% of these men having biochemical recurrence 10 years following radiotherapy (reference 3 in article). 92% of these men will undergo androgen deprivation therapy which is non-curative, and only 2% will undergo potentially curative salvage surgery (references 11-13 in article. Until recently, open salvage prostatectomy remained the only surgical treatment option for these patients with clinically localized recurrent prostate cancer.
Salvage robotic assisted laparoscopic radical prostatectomy (SRALP) performed by experienced robotic surgical centers has shown similar oncologic efficacy with improved continence rate and perioperative outcomes than the open counterpart (references 6, 21 and 39 from article). SRALP has limited long term follow-up, with few centers offering this as an alternative treatment. Further long term follow-up is warranted and SRALP should only be performed by well experienced robotic surgeons.
Written by:
Stephen B. Williams, MD as part of Beyond the Abstract on UroToday.com. This initiative offers a method of publishing for the professional urology community. Authors are given an opportunity to expand on the circumstances, limitations etc... of their research by referencing the published abstract.
Salvage robotic assisted laparoscopic radical prostatectomy: Indications and outcomes - Abstract
UroToday.com Prostate Cancer Section